CPDR Biospecimen Banks
New Challenges in Predicting the Clinical Course for CaP Patients
It is worth noting that well-characterized biospecimens from our group and others have already contributed immensely to the novel molecular discoveries made in the field of CaP research. Therefore, with a proven track record, the continued development and enhancement of the CPDR Biospecimen Bank holds great promise for much needed translational research at CPDR and at other institutions through collaborative research agreements.
The biospecimen storage and processing facilities that comprise the CPDR Biospecimen Bank are housed in four locations: the Walter Reed National Military Medical Center (WRNNMC) in Bethesda, MD; the headquarters of the Center for Prostate Disease Research (CPDR) in Rockville, MD; the Joint Pathology Center (JPC) in Washington, DC, and the Prostate Cell Center at the Department of Surgery of the Uniformed Services University (USU) in Bethesda, MD. These facilities have been processing biospecimens since 1993 and have a significant endowment of biospecimen resources. The biospecimen resources and analytical and processing services provided by these facilities have supported numerous studies conducted at the CPDR. These studies have resulted in over 60 peer-reviewed publications, 10 grants or CRADA, and five patents to date.
- Radical Prostatectomy Specimen Processing for Frozen Tissue Bank Generation
- Histological Characterization
- Radical Prostatectomy Specimen Processing for Fixed, Paraffin-embedded Tissue Bank Generation
- Laser Capture Microdissection (LCM) of Prostate Tissues and Generation of
LCM/RNA and Genomic DNA Bank
- Development of Tissue Microarrays (TMA)
- Peripheral Blood Collection and Processing to Generate Serum and genomic DNA Banks
- Serum Preparation
- Peripheral Blood DNA Bank
More recently, active collaborations have been sought by corporate partners and academic leaders to use CPDR Bio-specimens bank. A Biospecimen Oversight Committee and Research Opportunity Evaluation Committee have been instituted recently to monitor the prioritization of bio-specimens for in-house use and collaborations.
July 20, 2015
CPDR's GHI publication is featured in the latest MDLinx "Best of Oncology"
MDLinx has featured publication by Dr. Jennifer Cullen, et al., titled: A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer, listed as best of oncology.
Quarterly Guest Speaker
Dr. Stephen Lewis
Radiation Oncologist, WRNMMC
Presentation: "Cancer 101: Understanding Emerging Therapies in 2015"
(Discussion of new treatments in radiation therapy and other modalities including immunotherapies and targeted agents for many cancers).
Date: Thursday, August 6, 2015
Time: 7-8:30 PM
Location: WRNMMC, America Building, 2nd floor, Room 2525
Contact: COL (ret) Jane Hudak for more information at 301-319-2918 or
Read the August 2015 WRNMMC UsToo! Newsletter
April 21, 2014
Biological and Genomic Differences of ERG Oncoprotein-Stratified Prostate Cancers from African and Caucasian Americans
March 30, 2014
CytoTest and Uniformed Services University’s Center for Prostate Disease Research enter into CRADA to advance cancer diagnosis and prognosis